CLEARWATER, Fla., Jan. 31, 2017 /PRNewswire/ -- Bovie Medical Corporation (NYSE MKT: BVX), provided an update on its J-PlasmaŽ product.
TheCompany disclosed that it is exploring new sales channel partnerships to further scale J-PlasmaŽ in the gynecology specialty. The pilot program with Hologic that expires at the end of February 2017 will not be extended
Additionally, the Company announced that:
The Company will release its fourth quarter and full year 2016 financial results after market on Thursday, March 9th and hold its analyst/investor conference call to discuss its financial performance and latest J-PlasmaŽ developments on Friday morning, March 10th.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-PlasmaŽ, a patented new plasma-based surgical product for cutting and coagulation. J-PlasmaŽ utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company's own well-respected brands (BovieŽ, AaronŽ, IDS and ICON) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie Medical Corporation's www.boviemed.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bovie-medical-provides-j-plasma-update-300399799.html
SOURCE Bovie Medical Corporation
Subscribe to our Free Newsletters!